<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05612087</url>
  </required_header>
  <id_info>
    <org_study_id>2022-09-010C</org_study_id>
    <nct_id>NCT05612087</nct_id>
  </id_info>
  <brief_title>The Clinical Significance of Gut Permeability in Gastrointestinal Post Acute COVID-19 Syndrome</brief_title>
  <official_title>The Clinical Significance of Gut Permeability in Gastrointestinal Post Acute COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) and the associated coronavirus&#xD;
      disease 2019 (COVID-19) have been spreading all around the world for past 3 years. Some of&#xD;
      these convalescent individuals experienced long- term sequelae termed 'long COVID', or 'post-&#xD;
      acute COVID-19 syndrome'(PACS). Common manifestations are systemic, neuropsychiatric, cardio-&#xD;
      respiratory and gastrointestinal [1].&#xD;
&#xD;
      The prevalence of gastrointestinal PACS was 2-5% in different literatures [2][3]. The risk&#xD;
      factors of gastrointestinal PACS include anosmia, ageusia, and presence of chronic bowel&#xD;
      disease, dyspeptic symptoms and the psychological comorbidity [4]. Previous articles have&#xD;
      discussed pathogenesis of PACS, which was associated with increasing serum cytokine level and&#xD;
      persisted inflammatory status [5]. Whereas, the influence of chronic inflammation to target&#xD;
      organ has not been well studied. Liu et al explored the gut microbiota dynamics in patients&#xD;
      with PACS, which revealed higher levels of Ruminococcus gnavus, Bacteroides vulgatus and&#xD;
      lower levels of Faecalibacterium prausnitzii [6]. Another article established the association&#xD;
      between multisystem inflammatory syndrome in children (MIS-C) and zonulin-dependent loss of&#xD;
      gut mucosal barrier [7]. According to previous studies, infectious enteritis may cause&#xD;
      subsequent post infectious irritable bowel syndrome [8][9], which was associated with&#xD;
      increased gut permeability, T-lymphocyte, Mast cell and proinflammatory cytokine [10][11]. It&#xD;
      is reasonable that gastrointestinal PACS might be also associated with dysfunction of gut&#xD;
      mucosal barrier.&#xD;
&#xD;
      Confocal laser endomicroscopy (CLE) is a new endoscopic imaging tool that enables&#xD;
      visualization of gut mucosa changes. The gut permeability could be accessed by CLE in patient&#xD;
      with irritable bowel syndrome [12]. This study aimed to explore the association between gut&#xD;
      permeability and gastrointestinal PACS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>gut permeability</measure>
    <time_frame>3 months</time_frame>
    <description>leakage under Confocal laser endomicroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gut microbiome</measure>
    <time_frame>3 months</time_frame>
    <description>fecal microbiome</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastrointestinal Post Acute COVID-19 Syndrome</condition>
  <arm_group>
    <arm_group_label>gastrointestinal post acute COVID-19 syndrome</arm_group_label>
    <description>newly developped functional dyspepsia or irritable bowel syndrome after COVID-19 infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Confocal laser endomicroscopy</intervention_name>
    <description>Confocal laser endomicroscopy at jejunum, duodenum and stomach</description>
    <arm_group_label>gastrointestinal post acute COVID-19 syndrome</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      jejunum mucosa&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        persisted gastrointestinal symptoms such as dyspepsia, abdomen pain, diarrhea or&#xD;
        constipation 3 months after COVID-19 infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  persisted gastrointestinal symptoms such as dyspepsia, abdomen pain, diarrhea or&#xD;
             constipation 3 months after COVID-19 infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal cancer, surgical history of gastrointestinal tract, acute gastrointestinal&#xD;
             tract bleeding, allergy to fluorescein, pregnant or breast feeding, helicobacter&#xD;
             pylori infection, major cardiopulmonary disease, liver cirrhosis, end stage renal&#xD;
             disease, autoimmune disease, inflammtory bowel disease, small intestinal bacterial&#xD;
             overgrowth, celiac disease, type 1 diabetic mellitus, type II diabetic mellitus,&#xD;
             gastroenteritis in 3 months, history of irritable bowel syndrome, usage of NSAID,&#xD;
             steroid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu-Jen Chen, M.D</last_name>
    <phone>+88628712121</phone>
    <phone_ext>7506</phone_ext>
    <email>yzchen5@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Jen Chen, M.D</last_name>
      <phone>886228712121</phone>
      <phone_ext>7506</phone_ext>
      <email>yzchen5@vghtpe.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post acute COVID-19 syndrome</keyword>
  <keyword>gut permeability</keyword>
  <keyword>Confocal laser endomicroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

